The above findings support the idea that TRiC/CCT or CCT subunits may exert beneficial effects by decreasing the level of the toxic mHTT protein and increasing BDNF axonal transport in patients with HD (Figure 3A). Here, FLVCR2 is linked to Huntington disease.